The Leisure Travel Market Will Be Worth $15 Trillion by 2040, Report Says
That momentum isn't coming from the US or Europe, the report suggests.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Karl-Heinz Rummenigge disappointed Florian Wirtz chose Liverpool over Bayern Munich
Florian Wirtz is officially a Liverpool player having completed a move from Bayer Leverkusen for what has been reported to be an initial fee of €125 million fee with another €15 million in performance-based add-ons included. He's signed a five-year deal with the reigning Premier League champions, keeping him on Merseyside through 2030 and putting the proverbial nail in the coffin for Bayern Munich, who fully expected him to be joining them before Liverpool swooped in. For the better part of the past six to seven months, Bayern seemed like the natural, logical next step for Wirtz and the player himself indicated interest in making that leap. Former Bayern president Uli Hoeneß had been in routine contact with the player's family to try to seal the deal and explain the plan that the club had for the 22-year old, but in the end, he decided to go to Liverpool. It's been heavily suggested that conversations with manager Arne Slot had a lot to do with Wirtz choosing Liverpool over Bayern, especially knowing that he'll be solidified in the number 10 role there. Advertisement Former Bayern CEO Karl-Heinz Rummenigge expressed the sentiment shared by most Bayern fans when he recently expressed his disappointment with the German Rekordmeister having missed out on such a generational talent. 'Generally speaking, I think it's a pity. We've always had the philosophy that the best German players should play for FC Bayern. We gave it our all; in this case, no one made a mistake. It's Florian's decision – and we have to accept it,' Rummenigge explained in a recent interview with Welt Am Sonntag (via @iMiaSanMia). Meeting – 49th UEFA Ordinary Congress When both Rummenigge and Hoeneß were both still in office at Bayern, they had often dreamed about Hoeneß's desire for 'FC Deutschland,' in wanting to have all of the best German players playing for Bayern. The heavy contingent of Bayern players always being picked for the German national team were often reflective of that dream being, for all intents and purposes, somewhat of a reality, though it has started to trend in the opposite direction in recent years. Advertisement Nonetheless, Bayern is continuously competing with the undertones of top talents choosing the Premier League over the Bundesliga with the allure that the English top flight has. Harry Kane's move to Munich from Tottenham had hallmarks of helping reduce that polarity, but the economic state of disparity between the Premier League and the German top flight is always growing larger. More from
Yahoo
13 minutes ago
- Yahoo
Attention, Nvidia Shareholders: 1 Crucial Thing to Watch in the Second Half
Nvidia, after early headwinds, finished the first half of the year with a gain. The company reached a new milestone in recent days, one that could set the tone for share performance in the second half. 10 stocks we like better than Nvidia › The first half was a bit of a roller coaster ride for Nvidia (NASDAQ: NVDA) shareholders. The stock slid almost 30% from the start of the year to early April amid a variety of concerns -- from the future of artificial intelligence (AI) spending to worries that President Trump's import tariffs would weigh on the economy and corporate earnings. Meanwhile, the company continued to launch its new Blackwell platform and delivered double-digit quarterly revenue growth. The message for future prospects is bright too, with Nvidia speaking of soaring demand in the area of AI inference and launching projects abroad such as the building of AI infrastructure in Abu Dhabi. All of this, along with an easing of international trade tensions, prompted investors to return to growth stocks, and one of their top picks has been Nvidia -- the stock finished the first half with a 17% gain. Now, as we head into the second half of the year, you may be wondering how Nvidia will fare -- here's one crucial element to watch. Nvidia has built an amazing success story over the years, transforming itself from a company that mainly served the video gaming market to one that's at the center of one of today's highest growth industries. The graphic processing unit (GPU) still is integral to video games, but Nvidia -- thanks to sales of GPUs and related products and services -- today generates most of its revenue from AI customers. For example, in the latest quarter, data center revenue made up 88% of total revenue. This AI giant entered the AI market in its earliest days and aggressively built an empire. Today, selling the world's top-performing GPUs, Nvidia dominates the AI chip market and has pledged to update its chips -- and often complete architecture -- on an annual basis. It launched this annual rhythm with the Blackwell architecture and chip in the fourth quarter of last year -- the rollout went smoothly, Nvidia maintained gross margin in its forecast range, and Blackwell delivered $11 billion in revenue during its first quarter of commercialization. That represented a successful start to this fast-paced innovation plan, and this brings me to the point to watch now -- a new milestone for Nvidia -- as the second half begins. Nvidia's next launch is Blackwell Ultra, and it's already started as cloud player CoreWeave just announced the availability of the platform. CoreWeave now is offering customers access to GB300 NVL72, a system that's a step up from the original Blackwell and a leap from the Hopper architecture -- that was the main Nvidia architecture in use before the original Blackwell launch this winter. GB300 NVL72 may provide a fiftyfold jump in output for reasoning model inference compared to Hopper. Now, the point to watch is this Blackwell Ultra rollout, with special attention to demand and whether the process is smooth or not. And once earnings season rolls around, it will be important to look at sales figures as well as gross margin. If this latest update mirrors the Blackwell launch, investors may have something to cheer about -- and we'll have reason to be optimistic about the next chip launches too. Nvidia will have proved its ability to successfully handle frequent chip releases and maintain strong growth and profitability on sales. If there's a glitch along the way or if Nvidia misses a financial goal, then it will be important to dig deeper and examine whether this was just a one-time problem or something that could persist through the next product launches. This is crucial for Nvidia because its market leadership depends on this ability to innovate and successfully roll out a new product. Demand for Blackwell this winter, with it exceeding supply at certain moments, shows us customers are eager to get their hands on the next Nvidia innovation. That's positive, but Nvidia must smoothly deliver on promises in order to keep this momentum going. So far, with the Blackwell launch as a reference point, there's reason to be optimistic. And if Nvidia scores a win with the Blackwell Ultra launch too, the company could see its stock continue to march higher in the second half. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Attention, Nvidia Shareholders: 1 Crucial Thing to Watch in the Second Half was originally published by The Motley Fool
Forbes
14 minutes ago
- Forbes
Healthcare ETF Underperforms S&P 500: Price Charts Show How Much
Healthcare stocks The big healthcare stocks are not keeping up with wider stock market. When the S&P 500 and the Nasdaq 100 recently popped to new highs, this sector vastly underperformed it. It's likely the problem has to do with much investor concern about cuts to Medicaid and other 'big beautiful bill' adjustments. 4 Healthcare Stocks (And The ETF) Fail To Keep Up Healthcare Select Sector SPDR ETF: Healthcare Select Sector SPDR ETF, daily price chart, 7 7 25. The fund is way down from those October 2024 prices. The rally from mid-December 2024 to early March 2025 failed to make it above the previous autumn's highs. The 200-day moving average is trending downward. Note that the 50-day moving average crossed below the 200-day in mid-December 2024. The ETF has 60 holdings in the sector. Eli Lilly. Eli Lilly daily price chart, 7 7 25. One of the old-school brand names in the group, Eli Lilly has been in business for 150 years. The drug maker focuses on cancer, immunology, diabetes and obesity, among other areas. The company recently acquired Verve Therapeutics, a Boston firm working on cardiovascular treatments. The stock hit a peak in February of just above $930. It joined others dropping into April 7 where the price bottomed at near $675. A brief rally from there failed to close above a declining 200-day moving average and now Lilly trades under the 50-day moving average. Market cap is $732.48 billion. Johnson & Johnson Johnson & Johnson daily price chart, 7 7 25. With a market cap of $373.59 billion, the company is component of the Dow Jones Industrial Average and of the S&P 500. Johnson & Johnson is a household name: it's been around for 139 years. The price-earnings ratio is 17. The drug maker pays a dividend of 3.31%. The stock reached a peak in early March of $168. It's been unable to recover to anywhere near that level following the early April sell-off. Today's closing price puts it above both the 50-day and the 200-day moving averages. Abbvie AbbVie daily price chart, 7 7 25. The North Chicago-based drug manufacturer recently purchased biotech firm Capstan for $2.1 billion. In May, Citigroup downgraded their opinion of AbbVie from 'buy" to 'neutral' with a price target of $205. In April, Cantor Fitzgerald initiated coverage with an 'overweight' tag, price targeted for $210. AbbVie pays a 3.47% dividend. The price peaked in early March at near $216. The sell-off into early April was dramatic with a price drop to near $162.50. Today's close put it at just above the 50-day moving average and the 200-day moving average. Amgen Amgen daily price chart, 7 7 25. Amgen hit a peak of just above $330 in early March. The stock tanked in early April along with the market as a whole but never made it back to the high. Right now, the price is slightly above a down-trending 200-day moving average. Friday's high could not quite make it above the June high near $300. The drug manufacturer has a market cap of $157.52 billion. The Thousand Oaks, California-based company is a component of the Dow Jones Industrial Average, the S&P 500 and the Nasdaq 100. The stock trades with a price-earnings ratio of 26. Amgen pays a 3.29% dividend. Stats courtesy of Charts courtesy of No artificial intelligence was used in the writing of this post. More analysis and commentary at
